Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Verona Pharma assumed with an Outperform at Wedbush » 07:18
09/19/22
09/19
07:18
09/19/22
07:18
VRNA

Verona Pharma

$10.20 /

-0.66 (-6.08%)

Wedbush analyst Andreas…

Wedbush analyst Andreas Argyrides assumed coverage of Verona Pharma with an Outperform rating with a price target of $27, up from $23. The analyst notes Verona Pharma is an emerging pharmaceutical company developing ensifentrine for the treatment of respiratory diseases like chronic obstructive pulmonary disease, cystic fibrosis, and asthma. Argyrides views Verona shares as an opportunity to invest in a new class of inhaled treatment for not just COPD but also cystic fibrosis and asthma.

ShowHide Related Items >><<
VRNA Verona Pharma
$10.20 /

-0.66 (-6.08%)

VRNA Verona Pharma
$10.20 /

-0.66 (-6.08%)

08/29/22 H.C. Wainwright
Verona Pharma price target raised to $30 from $25 at H.C. Wainwright
08/26/22 Piper Sandler
Verona Pharma initiated with an Overweight at Piper Sandler
08/09/22 Canaccord
Verona Pharma price target raised to $27 from $24 at Canaccord
08/09/22 Wedbush
Verona Pharma price target raised to $23 from $18 at Wedbush
VRNA Verona Pharma
$10.20 /

-0.66 (-6.08%)

  • 11
    Aug
VRNA Verona Pharma
$10.20 /

-0.66 (-6.08%)

VRNA Verona Pharma
$10.20 /

-0.66 (-6.08%)

Options
Largest borrow rate increases among liquid names » 08:45
08/29/22
08/29
08:45
08/29/22
08:45
SST

System1

$10.88 /

-0.13 (-1.18%)

, EAR

Eargo

$1.88 /

-0.425 (-18.48%)

, TIGR

UP Fintech

$3.81 /

-0.03 (-0.78%)

, BRCC

BRC Inc.

$10.56 /

+0.16 (+1.54%)

, VRNA

Verona Pharma

$10.52 /

-0.09 (-0.85%)

, FREY

Freyr Battery

$12.29 /

-0.295 (-2.34%)

, PSTG

Pure Storage

$30.37 /

-0.68 (-2.19%)

, UUP

PowerShares DB US Dollar Index Up

$29.14 /

+0.11 (+0.38%)

, SEEL

Seelos Therapeutics

$1.21 /

-0.11 (-8.37%)

, RGS

Regis

$1.53 /

-0.1 (-6.13%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: System1 (SST) 300.34% +38.92, Eargo (EAR) 82.19% +2.68, UP Fintech Holding Ltd (TIGR) 34.10% +1.39, SilverBox Engaged Merger Corp (BRCC) 82.37% +1.04, Verona Pharma (VRNA) 5.07% +0.79, FREYR Battery (FREY) 6.94% +0.71, Pure Storage (PSTG) 0.66% +0.41, PowerShares DB US Dollar Index Bullish Fund (UUP) 1.36% +0.34, Seelos Therapeutics (SEEL) 2.81% +0.31, and Regis (RGS) 39.59% +0.31.

ShowHide Related Items >><<
VRNA Verona Pharma
$10.52 /

-0.09 (-0.85%)

SST System1
$10.88 /

-0.13 (-1.18%)

SEEL Seelos Therapeutics
$1.21 /

-0.11 (-8.37%)

RGS Regis
$1.53 /

-0.1 (-6.13%)

PSTG Pure Storage
$30.37 /

-0.68 (-2.19%)

FREY Freyr Battery
$12.29 /

-0.295 (-2.34%)

EAR Eargo
$1.88 /

-0.425 (-18.48%)

BRCC BRC Inc.
$10.56 /

+0.16 (+1.54%)

SST System1
$10.88 /

-0.13 (-1.18%)

08/12/22 DA Davidson
System1 price target lowered to $19 from $26 at DA Davidson
08/12/22 Benchmark
System1 price target lowered to $13 from $15 at Benchmark
07/11/22 BofA
BofA starts System1 at Buy with $12 price target
07/11/22 BofA
System1 initiated with a Buy at BofA
EAR Eargo
$1.88 /

-0.425 (-18.48%)

09/23/21
Fly Intel: Top five analyst downgrades
09/23/21 William Blair
William Blair downgrades Eargo on 'multiple unknowns' from criminal probe
09/23/21 Wells Fargo
Wells Fargo cuts Eargo to Equal Weight, slashes price target $10 from $52
09/23/21 William Blair
Eargo downgraded to Market Perform from Outperform at William Blair
TIGR UP Fintech
$3.81 /

-0.03 (-0.78%)

06/13/22 Daiwa
UP Fintech price target raised to $5.70 from $5.40 at Daiwa
05/19/22 China Renaissance
UP Fintech assumed with Hold from Buy at China Renaissance
12/01/21 Citi
UP Fintech price target lowered to $7.58 from $18.22 at Citi
10/29/21 Alliance Global Partners
MICT could benefit on top China brokers' fallout, says Alliance Global Partners
BRCC BRC Inc.
$10.56 /

+0.16 (+1.54%)

08/23/22 Tigress Financial
BRC Inc. price target raised to $19 from $17 at Tigress Financial
08/12/22 Truist
BRC Inc. price target lowered to $12 from $15 at Truist
08/01/22 Citi
BRC Inc. transferred with Neutral, $10 target at Citi
07/11/22 Citi
BRC Inc. price target lowered to $10 from $13 at Citi
VRNA Verona Pharma
$10.52 /

-0.09 (-0.85%)

08/29/22 H.C. Wainwright
Verona Pharma price target raised to $30 from $25 at H.C. Wainwright
08/26/22 Piper Sandler
Verona Pharma initiated with an Overweight at Piper Sandler
08/09/22 Canaccord
Verona Pharma price target raised to $27 from $24 at Canaccord
08/09/22 Wedbush
Verona Pharma price target raised to $23 from $18 at Wedbush
FREY Freyr Battery
$12.29 /

-0.295 (-2.34%)

08/24/22 Goldman Sachs
Freyr Battery upgraded to Buy from Neutral at Goldman Sachs
06/20/22 Goldman Sachs
Freyr Battery initiated with a Neutral at Goldman Sachs
03/17/22 US Capital Advisors
Freyr Battery initiated with a Buy at US Capital Advisors
01/26/22 Clarksons Platou
Freyr Battery initiated with a Buy at Clarksons Platou
PSTG Pure Storage
$30.37 /

-0.68 (-2.19%)

08/29/22 Evercore ISI
Pure Storage price target raised to $38 from $33 at Evercore ISI
08/16/22 Credit Suisse
Pure Storage initiated with an Outperform at Credit Suisse
06/28/22 Evercore ISI
Pure Storage price target lowered to $33 from $40 at Evercore ISI
06/02/22 Northland
Pure Storage price target raised to $44 from $42 at Northland
UUP PowerShares DB US Dollar Index Up
$29.14 /

+0.11 (+0.38%)

SEEL Seelos Therapeutics
$1.21 /

-0.11 (-8.37%)

03/14/22 B. Riley
Seelos Therapeutics price target lowered to $4 from $6 at B. Riley
03/08/22 Cantor Fitzgerald
Seelos Therapeutics price target lowered to $3 from $5 at Cantor Fitzgerald
01/24/22 B. Riley
Seelos Therapeutics price target lowered to $6 from $11 at B. Riley
11/24/21 Benchmark
Seelos Therapeutics' license acquisition 'positive,' says Benchmark
RGS Regis
$1.53 /

-0.1 (-6.13%)

09/16/21 Loop Capital
Regis price target lowered to $6 from $12 at Loop Capital
VRNA Verona Pharma
$10.52 /

-0.09 (-0.85%)

SST System1
$10.88 /

-0.13 (-1.18%)

PSTG Pure Storage
$30.37 /

-0.68 (-2.19%)

FREY Freyr Battery
$12.29 /

-0.295 (-2.34%)

EAR Eargo
$1.88 /

-0.425 (-18.48%)

BRCC BRC Inc.
$10.56 /

+0.16 (+1.54%)

  • 11
    Aug
RGS Regis
$1.53 /

-0.1 (-6.13%)

PSTG Pure Storage
$30.37 /

-0.68 (-2.19%)

VRNA Verona Pharma
$10.52 /

-0.09 (-0.85%)

SST System1
$10.88 /

-0.13 (-1.18%)

PSTG Pure Storage
$30.37 /

-0.68 (-2.19%)

FREY Freyr Battery
$12.29 /

-0.295 (-2.34%)

BRCC BRC Inc.
$10.56 /

+0.16 (+1.54%)

UUP PowerShares DB US Dollar Index Up
$29.14 /

+0.11 (+0.38%)

TIGR UP Fintech
$3.81 /

-0.03 (-0.78%)

SST System1
$10.88 /

-0.13 (-1.18%)

SEEL Seelos Therapeutics
$1.21 /

-0.11 (-8.37%)

RGS Regis
$1.53 /

-0.1 (-6.13%)

PSTG Pure Storage
$30.37 /

-0.68 (-2.19%)

FREY Freyr Battery
$12.29 /

-0.295 (-2.34%)

EAR Eargo
$1.88 /

-0.425 (-18.48%)

BRCC BRC Inc.
$10.56 /

+0.16 (+1.54%)

Recommendations
Verona Pharma price target raised to $30 from $25 at H.C. Wainwright » 06:11
08/29/22
08/29
06:11
08/29/22
06:11
VRNA

Verona Pharma

$10.52 /

-0.09 (-0.85%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on Verona Pharma to $30 from $25 and keeps a Buy rating on the shares. The analyst says the company's ENHANCE-2 results "prove highly favorable." Verona reported positive top-line data from the ENHANCE-2 pivotal Phase 3 trial of ensifentrine, its lead drug candidate for treatment of chronic obstructive pulmonary disease, Selvaraju tells investors in a research note. Ensifentrine is a first-in-class, dual inhibitor of the enzymes phosphodiesterase 3 and 4 combining bronchodilator and anti-inflammatory activities in one compound, says the analyst.

ShowHide Related Items >><<
VRNA Verona Pharma
$10.52 /

-0.09 (-0.85%)

VRNA Verona Pharma
$10.52 /

-0.09 (-0.85%)

08/26/22 Piper Sandler
Verona Pharma initiated with an Overweight at Piper Sandler
08/09/22 Canaccord
Verona Pharma price target raised to $27 from $24 at Canaccord
08/09/22 Wedbush
Verona Pharma price target raised to $23 from $18 at Wedbush
06/17/22 Wedbush
Verona Pharma price target lowered to $18 from $25 at Wedbush
VRNA Verona Pharma
$10.52 /

-0.09 (-0.85%)

  • 11
    Aug
VRNA Verona Pharma
$10.52 /

-0.09 (-0.85%)

Over a month ago
Initiation
Verona Pharma initiated with an Overweight at Piper Sandler » 04:43
08/26/22
08/26
04:43
08/26/22
04:43
VRNA

Verona Pharma

$10.61 /

-0.09 (-0.84%)

Piper Sandler analyst…

Piper Sandler analyst Yasmeen Rahimi initiated coverage of Verona Pharma with an Overweight rating and $31 price target. The shares are "significantly undervalued" based on the "compelling" data from the company's lead asset, ensifentrine, Rahimi tells investors in a research note. The analyst says ensifentrine "could be a game-changer" in the $10B chronic obstructive pulmonary disease market with greater than 1M addressable patients in the U.S. She expects $4.5B in peak sales for ensifentrine by 2035 only in U.S.

ShowHide Related Items >><<
VRNA Verona Pharma
$10.61 /

-0.09 (-0.84%)

VRNA Verona Pharma
$10.61 /

-0.09 (-0.84%)

08/09/22 Canaccord
Verona Pharma price target raised to $27 from $24 at Canaccord
08/09/22 Wedbush
Verona Pharma price target raised to $23 from $18 at Wedbush
06/17/22 Wedbush
Verona Pharma price target lowered to $18 from $25 at Wedbush
09/13/21
Fly Intel: Top five analyst initiations
VRNA Verona Pharma
$10.61 /

-0.09 (-0.84%)

  • 11
    Aug
VRNA Verona Pharma
$10.61 /

-0.09 (-0.84%)

Hot Stocks
Verona Pharma: Nuance Pharma cleared by CDE to begin trials with ensifentrine » 05:58
08/19/22
08/19
05:58
08/19/22
05:58
VRNA

Verona Pharma

$12.81 /

+0.78 (+6.48%)

Verona Pharma announces…

Verona Pharma announces its development partner, Nuance Pharma, has received clearance from the Center of Drug Evaluation for its Investigational New Drug application to conduct both Phase 1 and Phase 3 studies with ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease in mainland China. In 2021, Nuance Pharma entered into an agreement with Verona Pharma with a potential value of up to $219M, granting Nuance Pharma exclusive rights to develop and commercialize ensifentrine in Greater China. In return, Verona Pharma received an upfront payment of $25M in cash and an equity interest valued at $15M in Nuance Biotech, the parent company of Nuance Pharma. In addition, Verona Pharma is eligible to receive future milestone payments as well as double-digit royalties as a percentage of net sales in Greater China.

ShowHide Related Items >><<
VRNA Verona Pharma
$12.81 /

+0.78 (+6.48%)

VRNA Verona Pharma
$12.81 /

+0.78 (+6.48%)

08/09/22 Canaccord
Verona Pharma price target raised to $27 from $24 at Canaccord
08/09/22 Wedbush
Verona Pharma price target raised to $23 from $18 at Wedbush
06/17/22 Wedbush
Verona Pharma price target lowered to $18 from $25 at Wedbush
09/13/21
Fly Intel: Top five analyst initiations
VRNA Verona Pharma
$12.81 /

+0.78 (+6.48%)

  • 11
    Aug
VRNA Verona Pharma
$12.81 /

+0.78 (+6.48%)

Syndicate
Verona Pharma 12.4M share Secondary priced at $10.50 » 20:35
08/10/22
08/10
20:35
08/10/22
20:35
VRNA

Verona Pharma

$10.99 /

+0.95 (+9.46%)

The deal size was…

The deal size was increased to 12.4M ADSs from 10M ADSs and priced below last close of $10.90. Jefferies, Piper Sandler and Truist are acting as joint book running managers for the offering.

ShowHide Related Items >><<
VRNA Verona Pharma
$10.99 /

+0.95 (+9.46%)

VRNA Verona Pharma
$10.99 /

+0.95 (+9.46%)

08/09/22 Canaccord
Verona Pharma price target raised to $27 from $24 at Canaccord
08/09/22 Wedbush
Verona Pharma price target raised to $23 from $18 at Wedbush
06/17/22 Wedbush
Verona Pharma price target lowered to $18 from $25 at Wedbush
09/13/21
Fly Intel: Top five analyst initiations
VRNA Verona Pharma
$10.99 /

+0.95 (+9.46%)

  • 11
    Aug
VRNA Verona Pharma
$10.99 /

+0.95 (+9.46%)

On The Fly
What You Missed On Wall Street On Tuesday » 16:58
08/09/22
08/09
16:58
08/09/22
16:58
TSLA

Tesla

$850.00 /

-21.19 (-2.43%)

, MSFT

Microsoft

$282.38 /

+2.03 (+0.72%)

, PARA

Paramount

$24.69 /

-0.525 (-2.08%)

, PARAA

Paramount

$28.01 /

-0.585 (-2.05%)

, FOXA

Fox Corp.

$33.75 /

+0.275 (+0.82%)

, FOX

Fox Corp.

$31.35 /

+0.225 (+0.72%)

, DIS

Disney

$108.14 /

-0.98 (-0.90%)

, WMT

Walmart

$128.95 /

+1.33 (+1.04%)

, CMCSA

Comcast

$38.15 /

-0.44 (-1.14%)

, CMCSK

Comcast

$58.00 /

+ (+0.00%)

, APP

AppLovin

$36.04 /

-4.12 (-10.26%)

, U

Unity

$50.30 /

+0.59 (+1.19%)

, MU

Micron

$59.15 /

-2.31 (-3.76%)

, GFS

GlobalFoundries

$55.72 /

-3.485 (-5.89%)

, NVAX

Novavax

$40.26 /

-17.07 (-29.77%)

, RL

Ralph Lauren

$96.76 /

-4.54 (-4.48%)

, PLTR

Palantir

$9.25 /

-0.575 (-5.86%)

, BBBY

Bed Bath & Beyond

$9.79 /

-1.62 (-14.20%)

, NKE

Nike

$110.12 /

-3.88 (-3.40%)

, QSR

Restaurant Brands

$59.25 /

-0.02 (-0.03%)

, TNDM

TNDM

/

+

, VRNA

Verona Pharma

$10.04 /

+3.11 (+44.88%)

, MRSN

Mersana Therapeutics

$7.02 /

+1.755 (+33.37%)

, GSK

GSK

$40.00 /

-0.315 (-0.78%)

, ATRA

Atara Biotherapeutics

$4.71 /

+1.075 (+29.57%)

, QTRX

Quanterix

$7.43 /

-9.07 (-54.97%)

, VTNR

Vertex Energy

$7.80 /

-6.17 (-44.17%)

, BHC

Bausch Health

$5.18 /

-0.64 (-11.00%)

, NCLH

Norwegian Cruise Line

$12.10 /

-1.43 (-10.57%)

, UPST

Upstart

$28.45 /

-3.92 (-12.11%)

, GDRX

GoodRx

$7.81 /

+0.03 (+0.39%)

, SYY

Sysco

$82.36 /

-4.33 (-4.99%)

, IS

ironSource

$4.18 /

-0.55 (-11.63%)

, OWL

Blue Owl Capital

$12.44 /

-0.05 (-0.40%)

Get caught up quickly on…

ShowHide Related Items >><<
WMT Walmart
$128.95 /

+1.33 (+1.04%)

VTNR Vertex Energy
$7.80 /

-6.17 (-44.17%)

VRNA Verona Pharma
$10.04 /

+3.11 (+44.88%)

UPST Upstart
$28.45 /

-3.92 (-12.11%)

TSLA Tesla
$850.00 /

-21.19 (-2.43%)

TNDM TNDM
/

+

SYY Sysco
$82.36 /

-4.33 (-4.99%)

RL Ralph Lauren
$96.76 /

-4.54 (-4.48%)

QTRX Quanterix
$7.43 /

-9.07 (-54.97%)

QSR Restaurant Brands
$59.25 /

-0.02 (-0.03%)

PLTR Palantir
$9.25 /

-0.575 (-5.86%)

PARAA Paramount
$28.01 /

-0.585 (-2.05%)

PARA Paramount
$24.69 /

-0.525 (-2.08%)

OWL Blue Owl Capital
$12.44 /

-0.05 (-0.40%)

NVAX Novavax
$40.26 /

-17.07 (-29.77%)

NKE Nike
$110.12 /

-3.88 (-3.40%)

NCLH Norwegian Cruise Line
$12.10 /

-1.43 (-10.57%)

MU Micron
$59.15 /

-2.31 (-3.76%)

MSFT Microsoft
$282.38 /

+2.03 (+0.72%)

MRSN Mersana Therapeutics
$7.02 /

+1.755 (+33.37%)

IS ironSource
$4.18 /

-0.55 (-11.63%)

GSK GSK
$40.00 /

-0.315 (-0.78%)

GFS GlobalFoundries
$55.72 /

-3.485 (-5.89%)

GDRX GoodRx
$7.81 /

+0.03 (+0.39%)

FOXA Fox Corp.
$33.75 /

+0.275 (+0.82%)

FOX Fox Corp.
$31.35 /

+0.225 (+0.72%)

DIS Disney
$108.14 /

-0.98 (-0.90%)

CMCSK Comcast
$58.00 /

+ (+0.00%)

CMCSA Comcast
$38.15 /

-0.44 (-1.14%)

BHC Bausch Health
$5.18 /

-0.64 (-11.00%)

BBBY Bed Bath & Beyond
$9.79 /

-1.62 (-14.20%)

ATRA Atara Biotherapeutics
$4.71 /

+1.075 (+29.57%)

APP AppLovin
$36.04 /

-4.12 (-10.26%)

TSLA Tesla
$850.00 /

-21.19 (-2.43%)

08/08/22 Canaccord
Tesla price target raised to $881 from $815 at Canaccord
08/05/22 Susquehanna
Susquehanna downgrades Twitter on 'uncertainty and disruption' from takeover
08/03/22 Morgan Stanley
Tesla exposed to both risk and opportunity of battery race, says Morgan Stanley
08/02/22 Citi
Tesla price target raised to $424 from $375 at Citi
MSFT Microsoft
$282.38 /

+2.03 (+0.72%)

08/08/22 B. Riley
B. Riley thinks Globalstar's mystery satellite capacity customer is Apple
08/04/22 MKM Partners
8x8 initiated with a Neutral at MKM Partners
08/04/22 Deutsche Bank
Activision Blizzard price target lowered to $84 from $95 at Deutsche Bank
08/03/22 Craig-Hallum
RingCentral price target lowered to $110 from $175 at Craig-Hallum
PARA Paramount
$24.69 /

-0.525 (-2.08%)

08/05/22 Deutsche Bank
Paramount price target lowered to $32 from $35 at Deutsche Bank
08/05/22 JPMorgan
JPMorgan downgrades Paramount to Underweight on soft DTC revenue
08/05/22 Morgan Stanley
Paramount price target lowered to $20 from $22 at Morgan Stanley
08/05/22 JPMorgan
Paramount downgraded to Underweight from Neutral at JPMorgan
PARAA Paramount
$28.01 /

-0.585 (-2.05%)

FOXA Fox Corp.
$33.75 /

+0.275 (+0.82%)

07/27/22 Evercore ISI
Fox Corp. price target lowered to $38 from $44 at Evercore ISI
07/26/22 Goldman Sachs
Fox Corp. price target lowered to $30 from $32 at Goldman Sachs
07/18/22 Morgan Stanley
Fox Corp. downgraded to Equal Weight from Overweight at Morgan Stanley
05/25/22 Deutsche Bank
Fox Corp. price target lowered to $46 from $48 at Deutsche Bank
FOX Fox Corp.
$31.35 /

+0.225 (+0.72%)

06/02/22 Wolfe Research
Fox Corp. assumed at Peer Perform from Outperform at Wolfe Research
04/19/22 Rosenblatt
Fox Corp. initiated with a Neutral at Rosenblatt
12/14/21 Macquarie
Fox Corp. price target lowered to $37 from $40 at Macquarie
DIS Disney
$108.14 /

-0.98 (-0.90%)

08/10/22 Oppenheimer
Trade Desk price target raised to $78 from $60 at Oppenheimer
07/27/22 Evercore ISI
Disney price target lowered to $130 from $150 at Evercore ISI
07/26/22 Truist
Disney price target lowered to $125 from $135 at Truist
WMT Walmart
$128.95 /

+1.33 (+1.04%)

07/29/22 BofA
Amazon price target bumped to $170 at BofA after 'mostly positive' quarter
07/28/22 DA Davidson
Best Buy price target lowered to $88 from $110 at DA Davidson
07/28/22 Wells Fargo
Best Buy price target lowered to $70 from $82 at Wells Fargo
07/27/22 Deutsche Bank
Walmart price target lowered to $142 from $166 at Deutsche Bank
CMCSA Comcast
$38.15 /

-0.44 (-1.14%)

08/05/22 Redburn
Comcast downgraded to Neutral from Buy at Redburn
08/01/22 Barclays
Comcast downgraded to Equal Weight from Overweight at Barclays
07/29/22 Cowen
Comcast price target lowered to $51 from $60 at Cowen
07/29/22 Morgan Stanley
Comcast price target lowered to $50 from $55 at Morgan Stanley
CMCSK Comcast
$58.00 /

+ (+0.00%)

07/20/22 KeyBanc
Disney price target lowered to $131 from $151 at KeyBanc
05/23/22 Raymond James
Electronic Arts moves 'somewhat unexpected,' says Raymond James
04/14/22 Oppenheimer
Comcast price target lowered to $60 from $75 at Oppenheimer
03/23/22 Craig-Hallum
ComScore poised for share gains in local measurement, says Craig-Hallum
APP AppLovin
$36.04 /

-4.12 (-10.26%)

08/10/22 Benchmark
Benchmark keeps Sell rating on Unity, doesn't think AppLovin acquires
08/10/22 Barclays
Unity price target raised to $49 from $35 at Barclays
08/10/22 Piper Sandler
Unity price target raised to $42 from $34 at Piper Sandler
08/09/22 Stifel
Unity price target raised to $60 at Stifel after AppLovin proposal
U Unity
$50.30 /

+0.59 (+1.19%)

08/10/22 Oppenheimer
Unity price target raised to $60 from $54 at Oppenheimer
MU Micron
$59.15 /

-2.31 (-3.76%)

08/10/22 Citi
Micron price target lowered to $75 from $80 at Citi
08/09/22 Piper Sandler
Micron weakness in PCs, phones spilling to other markets, says Piper Sandler
08/09/22 Raymond James
Micron downgraded to Outperform at Raymond James on near-term headwinds
08/09/22 Raymond James
Micron downgraded to Outperform from Strong Buy at Raymond James
GFS GlobalFoundries
$55.72 /

-3.485 (-5.89%)

08/10/22 Citi
GlobalFoundries price target lowered to $67 from $70 at Citi
07/27/22 Baird
CHIPS Act could have deflationary impact on semiconductors, says Baird
07/20/22 Deutsche Bank
GlobalFoundries price target lowered to $55 from $70 at Deutsche Bank
07/11/22 Susquehanna
GlobalFoundries price target lowered to $75 from $85 at Susquehanna
NVAX Novavax
$40.26 /

-17.07 (-29.77%)

08/09/22 Cowen
Novavax price target lowered to $110 from $150 at Cowen
07/22/22 B. Riley
Novavax price target lowered to $171 from $181 at B. Riley
06/08/22 B. Riley
B. Riley sees front line status for Novavax vaccine as mRNA alternative
06/08/22 Cowen
Novavax positive advisory vote removes major overhang, says Cowen
RL Ralph Lauren
$96.76 /

-4.54 (-4.48%)

08/05/22 Credit Suisse
Ralph Lauren price target lowered to $120 from $130 at Credit Suisse
08/01/22 Deutsche Bank
Ralph Lauren price target lowered to $99 from $101 at Deutsche Bank
07/21/22 Goldman Sachs
Ralph Lauren price target lowered to $78 from $85 at Goldman Sachs
07/15/22 UBS
Ralph Lauren price target lowered to $129 from $162 at UBS
PLTR Palantir
$9.25 /

-0.575 (-5.86%)

08/09/22 Morgan Stanley
Palantir price target lowered to $11 from $13 at Morgan Stanley
08/09/22 Citi
Palantir price target lowered to $6 from $7 at Citi
08/09/22 Deutsche Bank
Palantir downgraded to Sell from Hold at Deutsche Bank
08/08/22 Jefferies
Palantir price target lowered to $12 from $13 at Jefferies
BBBY Bed Bath & Beyond
$9.79 /

-1.62 (-14.20%)

08/09/22 Baird
Baird downgrades Bed Bath & Beyond to sell after 86% two-day rally
08/09/22 Baird
Bed Bath & Beyond downgraded to Underperform from Neutral at Baird
08/08/22 Odeon Capital
Bed Bath & Beyond cut to Hold at Odeon Capital following doubling in a week
08/08/22 Odeon Capital
Bed Bath & Beyond downgraded to Hold from Buy at Odeon Capital
NKE Nike
$110.12 /

-3.88 (-3.40%)

08/09/22 Exane BNP Paribas
Nike downgraded to Neutral at Exane BNP Paribas on concerns about FY25 targets
08/09/22 Exane BNP Paribas
Nike downgraded to Neutral from Outperform at Exane BNP Paribas
07/25/22 Piper Sandler
Nike assumed with a Neutral at Piper Sandler
07/21/22 KeyBanc
KeyBanc transitions coverage of Global Brands & E-Commerce with cautious view
QSR Restaurant Brands
$59.25 /

-0.02 (-0.03%)

08/09/22 Argus
Restaurant Brands upgraded to Buy at Argus on earnings upside
08/09/22 Argus
Restaurant Brands upgraded to Buy from Hold at Argus
08/05/22 Baird
Restaurant Brands price target raised to $63 from $56 at Baird
08/05/22 Deutsche Bank
Restaurant Brands price target raised to $70 from $64 at Deutsche Bank
TNDM TNDM
/

+

08/09/22 Wells Fargo
Tandem Diabetes downgraded to Underweight from Overweight at Wells Fargo
08/04/22 Craig-Hallum
Tandem Diabetes price target lowered to $105 from $156 at Craig-Hallum
08/04/22 Lake Street
Tandem Diabetes price target lowered to $150 from $200 at Lake Street
08/04/22 Cowen
Tandem Diabetes price target lowered to $107 from $141 at Cowen
VRNA Verona Pharma
$10.04 /

+3.11 (+44.88%)

08/09/22 Canaccord
Verona Pharma price target raised to $27 from $24 at Canaccord
08/09/22 Wedbush
Verona Pharma price target raised to $23 from $18 at Wedbush
06/17/22 Wedbush
Verona Pharma price target lowered to $18 from $25 at Wedbush
09/13/21
Fly Intel: Top five analyst initiations
MRSN Mersana Therapeutics
$7.02 /

+1.755 (+33.37%)

08/09/22 Baird
Mersana Therapeutics price target raised to $20 from $18 at Baird
05/10/22 Baird
Mersana Therapeutics price target lowered to $18 from $23 at Baird
05/09/22 H.C. Wainwright
Mersana price target lowered to $19 from $24 at H.C. Wainwright
11/10/21 Baird
Mersana Therapeutics price target lowered to $23 from $30 at Baird
GSK GSK
$40.00 /

-0.315 (-0.78%)

08/08/22 UBS
GSK plc price target lowered to 1,820 GBp from 1,860 GBp at UBS
08/05/22 Morgan Stanley
GSK plc resumed with an Equal Weight at Morgan Stanley
07/21/22 Citi
GSK plc resumed with a Neutral at Citi
ATRA Atara Biotherapeutics
$4.71 /

+1.075 (+29.57%)

07/20/22 Citi
Atara Biotherapeutics downgraded to Sell from Neutral at Citi
07/13/22 Canaccord
Atara Biotherapeutics price target lowered to $50 from $67 at Canaccord
07/13/22 Stifel
Stifel downgrades Atara Biotherapeutics to Hold following ATA188 analysis
07/13/22 Stifel
Atara Biotherapeutics downgraded to Hold from Buy at Stifel
QTRX Quanterix
$7.43 /

-9.07 (-54.97%)

08/09/22 Cowen
Quanterix downgraded to Market Perform from Outperform at Cowen
08/09/22 SVB Securities
Quanterix downgraded to Market Perform from Outperform at SVB Securities
05/11/22 Cowen
Quanterix price target lowered to $38 from $60 at Cowen
03/15/22 BTIG
Quanterix price target lowered to $60 from $92 at BTIG
VTNR Vertex Energy
$7.80 /

-6.17 (-44.17%)

08/10/22 Oppenheimer
Vertex Energy downgraded to Perform from Outperform at Oppenheimer
08/10/22 H.C. Wainwright
Vertex Energy price target lowered to $15 from $25 at H.C. Wainwright
07/07/22 Oppenheimer
Vertex Energy initiated with an Outperform at Oppenheimer
06/08/22 Stifel
Vertex Energy price target raised to $20 from $14 at Stifel
BHC Bausch Health
$5.18 /

-0.64 (-11.00%)

07/29/22 RBC Capital
Bausch Health downgraded to Sector Perform from Outperform at RBC Capital
07/29/22 RBC Capital
Bausch Health downgraded to Sector Perform from Outperform at RBC Capital
07/28/22 Truist
Bausch Health downgraded to Hold from Buy at Truist
07/28/22 Stifel
Stifel puts Bausch rating under review amid 'significant confusion'
NCLH Norwegian Cruise Line
$12.10 /

-1.43 (-10.57%)

08/10/22 Credit Suisse
Norwegian Cruise Line price target lowered to $25 from $33 at Credit Suisse
06/29/22 Barclays
Barclays initiates cruise line space with Royal Caribbean top pick
06/28/22 Barclays
Norwegian Cruise Line initiated with an Equal Weight at Barclays
06/21/22 Deutsche Bank
Norwegian Cruise Line price target lowered to $17 from $23 at Deutsche Bank
UPST Upstart
$28.45 /

-3.92 (-12.11%)

08/09/22 Morgan Stanley
Upstart origination volume may have peaked, says Morgan Stanley
08/09/22 Stephens
Upstart price target lowered to $23 from $28 at Stephens
07/22/22 Morgan Stanley
Berkshire Hills halting additions of new Upstart loans, says Morgan Stanley
07/18/22 Piper Sandler
Upstart price target lowered to $25 from $44 at Piper Sandler
GDRX GoodRx
$7.81 /

+0.03 (+0.39%)

08/09/22 Goldman Sachs
Goldman Sachs raises GoodRx price target to $10 amid grocer issue resolution
08/09/22 RBC Capital
GoodRx price target raised to $11 from $6.50 at RBC Capital
08/09/22 Barclays
GoodRx price target raised to $13 from $12 at Barclays
07/20/22 Barclays
GoodRx price target lowered to $12 from $15 at Barclays
SYY Sysco
$82.36 /

-4.33 (-4.99%)

08/10/22 Credit Suisse
Sysco price target lowered to $100 from $107 at Credit Suisse
06/29/22 Barclays
Sysco price target raised to $102 from $97 at Barclays
06/09/22 Barclays
Sysco price target lowered to $97 from $102 at Barclays
05/26/22 JPMorgan
Sysco upgraded to Overweight after recent pullback at JPMorgan
IS ironSource
$4.18 /

-0.55 (-11.63%)

08/03/22 Stifel
AppLovin price target lowered to $50 from $80 at Stifel
07/22/22 KeyBanc
ironSource downgraded to Sector Weight from Overweight at KeyBanc
OWL Blue Owl Capital
$12.44 /

-0.05 (-0.40%)

07/11/22 JPMorgan
Blue Owl Capital initiated with a Neutral at JPMorgan (Thursday)
06/08/22 JMP Securities
Blue Owl Capital initiated with an Outperform at JMP Securities
01/24/22 BofA
Blue Owl Capital initiated with a Buy at BofA
01/24/22 BofA
Blue Owl Capital initiated with a Buy at BofA
WMT Walmart
$128.95 /

+1.33 (+1.04%)

VTNR Vertex Energy
$7.80 /

-6.17 (-44.17%)

VRNA Verona Pharma
$10.04 /

+3.11 (+44.88%)

UPST Upstart
$28.45 /

-3.92 (-12.11%)

U Unity
$50.30 /

+0.59 (+1.19%)

TSLA Tesla
$850.00 /

-21.19 (-2.43%)

TNDM TNDM
/

+

SYY Sysco
$82.36 /

-4.33 (-4.99%)

RL Ralph Lauren
$96.76 /

-4.54 (-4.48%)

QTRX Quanterix
$7.43 /

-9.07 (-54.97%)

QSR Restaurant Brands
$59.25 /

-0.02 (-0.03%)

PLTR Palantir
$9.25 /

-0.575 (-5.86%)

PARA Paramount
$24.69 /

-0.525 (-2.08%)

OWL Blue Owl Capital
$12.44 /

-0.05 (-0.40%)

NVAX Novavax
$40.26 /

-17.07 (-29.77%)

NKE Nike
$110.12 /

-3.88 (-3.40%)

NCLH Norwegian Cruise Line
$12.10 /

-1.43 (-10.57%)

MU Micron
$59.15 /

-2.31 (-3.76%)

MSFT Microsoft
$282.38 /

+2.03 (+0.72%)

MRSN Mersana Therapeutics
$7.02 /

+1.755 (+33.37%)

IS ironSource
$4.18 /

-0.55 (-11.63%)

GSK GSK
$40.00 /

-0.315 (-0.78%)

GFS GlobalFoundries
$55.72 /

-3.485 (-5.89%)

GDRX GoodRx
$7.81 /

+0.03 (+0.39%)

FOXA Fox Corp.
$33.75 /

+0.275 (+0.82%)

DIS Disney
$108.14 /

-0.98 (-0.90%)

CMCSA Comcast
$38.15 /

-0.44 (-1.14%)

BHC Bausch Health
$5.18 /

-0.64 (-11.00%)

BBBY Bed Bath & Beyond
$9.79 /

-1.62 (-14.20%)

ATRA Atara Biotherapeutics
$4.71 /

+1.075 (+29.57%)

APP AppLovin
$36.04 /

-4.12 (-10.26%)

  • 11
    Aug
  • 02
    Jun
  • 08
    Dec
  • 03
    Dec
  • 16
    Nov
  • 28
    Oct
WMT Walmart
$128.95 /

+1.33 (+1.04%)

U Unity
$50.30 /

+0.59 (+1.19%)

TSLA Tesla
$850.00 /

-21.19 (-2.43%)

RL Ralph Lauren
$96.76 /

-4.54 (-4.48%)

PLTR Palantir
$9.25 /

-0.575 (-5.86%)

PARAA Paramount
$28.01 /

-0.585 (-2.05%)

PARA Paramount
$24.69 /

-0.525 (-2.08%)

OWL Blue Owl Capital
$12.44 /

-0.05 (-0.40%)

NVAX Novavax
$40.26 /

-17.07 (-29.77%)

NKE Nike
$110.12 /

-3.88 (-3.40%)

NCLH Norwegian Cruise Line
$12.10 /

-1.43 (-10.57%)

MU Micron
$59.15 /

-2.31 (-3.76%)

MSFT Microsoft
$282.38 /

+2.03 (+0.72%)

GSK GSK
$40.00 /

-0.315 (-0.78%)

GFS GlobalFoundries
$55.72 /

-3.485 (-5.89%)

FOXA Fox Corp.
$33.75 /

+0.275 (+0.82%)

FOX Fox Corp.
$31.35 /

+0.225 (+0.72%)

DIS Disney
$108.14 /

-0.98 (-0.90%)

CMCSA Comcast
$38.15 /

-0.44 (-1.14%)

BHC Bausch Health
$5.18 /

-0.64 (-11.00%)

BBBY Bed Bath & Beyond
$9.79 /

-1.62 (-14.20%)

APP AppLovin
$36.04 /

-4.12 (-10.26%)

WMT Walmart
$128.95 /

+1.33 (+1.04%)

VTNR Vertex Energy
$7.80 /

-6.17 (-44.17%)

U Unity
$50.30 /

+0.59 (+1.19%)

TSLA Tesla
$850.00 /

-21.19 (-2.43%)

TNDM TNDM
/

+

RL Ralph Lauren
$96.76 /

-4.54 (-4.48%)

PLTR Palantir
$9.25 /

-0.575 (-5.86%)

PARAA Paramount
$28.01 /

-0.585 (-2.05%)

PARA Paramount
$24.69 /

-0.525 (-2.08%)

OWL Blue Owl Capital
$12.44 /

-0.05 (-0.40%)

NVAX Novavax
$40.26 /

-17.07 (-29.77%)

NKE Nike
$110.12 /

-3.88 (-3.40%)

NCLH Norwegian Cruise Line
$12.10 /

-1.43 (-10.57%)

MU Micron
$59.15 /

-2.31 (-3.76%)

MSFT Microsoft
$282.38 /

+2.03 (+0.72%)

MRSN Mersana Therapeutics
$7.02 /

+1.755 (+33.37%)

IS ironSource
$4.18 /

-0.55 (-11.63%)

GSK GSK
$40.00 /

-0.315 (-0.78%)

GFS GlobalFoundries
$55.72 /

-3.485 (-5.89%)

FOXA Fox Corp.
$33.75 /

+0.275 (+0.82%)

FOX Fox Corp.
$31.35 /

+0.225 (+0.72%)

DIS Disney
$108.14 /

-0.98 (-0.90%)

CMCSK Comcast
$58.00 /

+ (+0.00%)

CMCSA Comcast
$38.15 /

-0.44 (-1.14%)

BHC Bausch Health
$5.18 /

-0.64 (-11.00%)

BBBY Bed Bath & Beyond
$9.79 /

-1.62 (-14.20%)

ATRA Atara Biotherapeutics
$4.71 /

+1.075 (+29.57%)

APP AppLovin
$36.04 /

-4.12 (-10.26%)

WMT Walmart
$128.95 /

+1.33 (+1.04%)

VTNR Vertex Energy
$7.80 /

-6.17 (-44.17%)

UPST Upstart
$28.45 /

-3.92 (-12.11%)

U Unity
$50.30 /

+0.59 (+1.19%)

TSLA Tesla
$850.00 /

-21.19 (-2.43%)

SYY Sysco
$82.36 /

-4.33 (-4.99%)

PLTR Palantir
$9.25 /

-0.575 (-5.86%)

PARAA Paramount
$28.01 /

-0.585 (-2.05%)

PARA Paramount
$24.69 /

-0.525 (-2.08%)

NVAX Novavax
$40.26 /

-17.07 (-29.77%)

NKE Nike
$110.12 /

-3.88 (-3.40%)

NCLH Norwegian Cruise Line
$12.10 /

-1.43 (-10.57%)

MU Micron
$59.15 /

-2.31 (-3.76%)

MSFT Microsoft
$282.38 /

+2.03 (+0.72%)

GSK GSK
$40.00 /

-0.315 (-0.78%)

GFS GlobalFoundries
$55.72 /

-3.485 (-5.89%)

GDRX GoodRx
$7.81 /

+0.03 (+0.39%)

DIS Disney
$108.14 /

-0.98 (-0.90%)

CMCSA Comcast
$38.15 /

-0.44 (-1.14%)

BHC Bausch Health
$5.18 /

-0.64 (-11.00%)

BBBY Bed Bath & Beyond
$9.79 /

-1.62 (-14.20%)

APP AppLovin
$36.04 /

-4.12 (-10.26%)

Syndicate
Verona Pharma announces offering of 10M ADSs » 16:29
08/09/22
08/09
16:29
08/09/22
16:29
VRNA

Verona Pharma

$10.04 /

+3.11 (+44.88%)

Verona Pharma announced a…

Verona Pharma announced a proposed underwritten public offering of 10M American Depositary Shares, each representing eight ordinary shares of Verona Pharma. Jefferies, Piper Sandler & Co. and Truist Securities are acting as the book-running managers for the Offering.

ShowHide Related Items >><<
VRNA Verona Pharma
$10.04 /

+3.11 (+44.88%)

VRNA Verona Pharma
$10.04 /

+3.11 (+44.88%)

08/09/22 Canaccord
Verona Pharma price target raised to $27 from $24 at Canaccord
08/09/22 Wedbush
Verona Pharma price target raised to $23 from $18 at Wedbush
06/17/22 Wedbush
Verona Pharma price target lowered to $18 from $25 at Wedbush
VRNA Verona Pharma
$10.04 /

+3.11 (+44.88%)

VRNA Verona Pharma
$10.04 /

+3.11 (+44.88%)

Recommendations
Verona Pharma price target raised to $27 from $24 at Canaccord » 15:08
08/09/22
08/09
15:08
08/09/22
15:08
VRNA

Verona Pharma

$9.13 /

+2.2 (+31.75%)

Canaccord analyst Edward…

Canaccord analyst Edward Nash raised the firm's price target on Verona Pharma to $27 from $24 and keeps a Buy rating on the shares after the company reported Q2 results and announced "positive" top-line data from the Phase III ENHANCE-2 study. Nash said that the Phase III ENHANCE-1 study is on track to report topline date in 2H22, and if results continue to be positive, the company anticipates filling an NDA for ensifentrine. The analyst added that a strong balance sheet with sufficient cash on hand will fund operations at Verona through 2023.

ShowHide Related Items >><<
VRNA Verona Pharma
$9.13 /

+2.2 (+31.75%)

VRNA Verona Pharma
$9.13 /

+2.2 (+31.75%)

08/09/22 Wedbush
Verona Pharma price target raised to $23 from $18 at Wedbush
06/17/22 Wedbush
Verona Pharma price target lowered to $18 from $25 at Wedbush
09/13/21
Fly Intel: Top five analyst initiations
09/13/21 H.C. Wainwright
Verona Pharma initiated with a Buy at H.C. Wainwright
VRNA Verona Pharma
$9.13 /

+2.2 (+31.75%)

VRNA Verona Pharma
$9.13 /

+2.2 (+31.75%)

Recommendations
Verona Pharma price target raised to $23 from $18 at Wedbush » 15:03
08/09/22
08/09
15:03
08/09/22
15:03
VRNA

Verona Pharma

$9.34 /

+2.41 (+34.78%)

Wedbush analyst Liana…

Wedbush analyst Liana Moussatos raised the firm's price target on Verona Pharma to $23 from $18 and keeps an Outperform rating on the shares after the company announced its Phase 3 ENHANCE-2 trial evaluating nebulized ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease, or COPD, successfully met its primary endpoint as well as secondary endpoints.

ShowHide Related Items >><<
VRNA Verona Pharma
$9.34 /

+2.41 (+34.78%)

VRNA Verona Pharma
$9.34 /

+2.41 (+34.78%)

06/17/22 Wedbush
Verona Pharma price target lowered to $18 from $25 at Wedbush
09/13/21
Fly Intel: Top five analyst initiations
09/13/21 H.C. Wainwright
Verona Pharma initiated with a Buy at H.C. Wainwright
VRNA Verona Pharma
$9.34 /

+2.41 (+34.78%)

VRNA Verona Pharma
$9.34 /

+2.41 (+34.78%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.